{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:05:21Z","timestamp":1787025921156,"version":"build-2736575974"},"reference-count":60,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0224","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:25:57Z","timestamp":1734337557000},"source":"Crossref","is-referenced-by-count":6,"title":["Psilocybin as a disease-modifying drug\u2014a salutogenic approach in psychiatry"],"prefix":"10.3238","author":[{"given":"Moritz","family":"Spangemacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea J.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca V.","family":"F\u00e4rber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jungaberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Jungaberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"10.3238\/arztebl.m2024.0224_ref1","unstructured":"Statistisches Bundesamt: Krankenh\u00e4user nach Fachabteilungen, 2024. www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Krankenhaeuser\/Tabellen\/krankenhaeuser-fa.html (last accessed on 10 September 2024)."},{"key":"10.3238\/arztebl.m2024.0224_ref2","doi-asserted-by":"crossref","unstructured":"Ludwig WD, M\u00fchlbauer B, Seifert R: Arzneiverordnungs-Report 2023. Berlin, Heidelberg: Springer 2024.","DOI":"10.1007\/978-3-662-68371-2"},{"key":"10.3238\/arztebl.m2024.0224_ref3","doi-asserted-by":"crossref","unstructured":"Ormel J, Hollon SD, Kessler RC, Cuijpers P, Monroe SM: More treatment but no less depression: the treatment-prevalence paradox. Clin Psychol Rev 2022; 91: 102111.","DOI":"10.1016\/j.cpr.2021.102111"},{"key":"10.3238\/arztebl.m2024.0224_ref4","unstructured":"McGrath JJ, Al-Hamzawi A, Alonso J, et al.: Age of onset and cumulative risk of mental disorders: a cross-national analysis of population surveys from 29 countries. Lancet Psychiatry 2023; 10: 668–81."},{"key":"10.3238\/arztebl.m2024.0224_ref5","doi-asserted-by":"crossref","unstructured":"Cipriani A, Furukawa TA, Salanti G, et al.: Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–66.","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"10.3238\/arztebl.m2024.0224_ref6","doi-asserted-by":"crossref","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40.","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"10.3238\/arztebl.m2024.0224_ref7","doi-asserted-by":"crossref","unstructured":"IsHak WW, Greenberg JM, Balayan K, et al.: Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry 2011; 19: 229–39.","DOI":"10.3109\/10673229.2011.614099"},{"key":"10.3238\/arztebl.m2024.0224_ref8","doi-asserted-by":"crossref","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17.","DOI":"10.1176\/appi.ajp.163.11.1905"},{"key":"10.3238\/arztebl.m2024.0224_ref9","doi-asserted-by":"crossref","unstructured":"Fava GA: May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Ther Adv Psychopharmacol 2020; 10: 2045125320970325.","DOI":"10.1177\/2045125320970325"},{"key":"10.3238\/arztebl.m2024.0224_ref10","doi-asserted-by":"crossref","unstructured":"Berlim MT, Turecki G: Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007; 52: 46–54.","DOI":"10.1177\/070674370705200108"},{"key":"10.3238\/arztebl.m2024.0224_ref11","doi-asserted-by":"crossref","unstructured":"Baldessarini RJ, Tondo L, Ghiani C, Lepri B: Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167: 934–41.","DOI":"10.1176\/appi.ajp.2010.09060880"},{"key":"10.3238\/arztebl.m2024.0224_ref12","doi-asserted-by":"crossref","unstructured":"Sahker E, Furukawa TA, Luo Y, Ferreira ML, Okazaki K, Chevance A, et al.: Estimating the smallest worthwhile difference of antidepressants: a cross-sectional survey. BMJ Ment Health 2024; 27: e300919.","DOI":"10.1136\/bmjment-2023-300919"},{"key":"10.3238\/arztebl.m2024.0224_ref13","doi-asserted-by":"crossref","unstructured":"Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA: The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry 2023; 28: 3243–56.","DOI":"10.1038\/s41380-022-01661-0"},{"key":"10.3238\/arztebl.m2024.0224_ref14","doi-asserted-by":"crossref","unstructured":"Ghaemi SN: Symptomatic versus disease-modifying effects of psychiatric drugs. Acta Psychiatrica Scandinavica 2022; 146: 251–7.","DOI":"10.1111\/acps.13459"},{"key":"10.3238\/arztebl.m2024.0224_ref15","doi-asserted-by":"crossref","unstructured":"Mittelmark MB, Bauer GF, Vaandrager L, Pelikan JM, Sagy S, Eriksson M, et al.: The handbook of salutogenesis. Springer 2022.","DOI":"10.1007\/978-3-030-79515-3"},{"key":"10.3238\/arztebl.m2024.0224_ref16","unstructured":"Antonovsky A: Health, stress and coping: new perspectives on mental and physical well-being. San Francisco: Jossey-Bass 1979."},{"key":"10.3238\/arztebl.m2024.0224_ref17","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnder G, Jungaberle H: The potential role of psychedelic drugs in mental health care of the future. Pharmacopsychiatry 2021; 54: 191–9.","DOI":"10.1055\/a-1486-7386"},{"key":"10.3238\/arztebl.m2024.0224_ref18","doi-asserted-by":"crossref","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, B\u00e4bler A, Vogel H, Hell D: Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 9: 3897–902.","DOI":"10.1097\/00001756-199812010-00024"},{"key":"10.3238\/arztebl.m2024.0224_ref19","doi-asserted-by":"crossref","unstructured":"Yaden DB, Griffiths RR: The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci 2021; 4: 568–72.","DOI":"10.1021\/acsptsci.0c00194"},{"key":"10.3238\/arztebl.m2024.0224_ref20","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnder G, Brand M, Mertens LJ, et al.: Treatment with psychedelics is psychotherapy: beyond reductionism. Lancet Psychiatry 2024; 11: 231–6.","DOI":"10.1016\/S2215-0366(23)00363-2"},{"key":"10.3238\/arztebl.m2024.0224_ref21","doi-asserted-by":"crossref","unstructured":"Nardou R, Sawyer E, Song YJ, et al.: Psychedelics reopen the social reward learning critical period. Nature 2023; 618: 790–8.","DOI":"10.1038\/s41586-023-06204-3"},{"key":"10.3238\/arztebl.m2024.0224_ref22","doi-asserted-by":"crossref","unstructured":"Daws RE, Timmermann C, Giribaldi B, et al.: Increased global integration in the brain after psilocybin therapy for depression. Nature medicine 2022; 28: 844–51.","DOI":"10.1038\/s41591-022-01744-z"},{"key":"10.3238\/arztebl.m2024.0224_ref23","doi-asserted-by":"crossref","unstructured":"Deco G, Sanz Perl Y, Johnson S, Bourke N, Carhart-Harris RL, Kringelbach ML: Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression. Nature Mental Health 2024: 1–15.","DOI":"10.1038\/s44220-024-00298-y"},{"key":"10.3238\/arztebl.m2024.0224_ref24","doi-asserted-by":"crossref","unstructured":"Reed MB, Vanicek T, Seiger R, et al.: Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval. Neuroimage 2021; 236: 118039.","DOI":"10.1016\/j.neuroimage.2021.118039"},{"key":"10.3238\/arztebl.m2024.0224_ref25","doi-asserted-by":"crossref","unstructured":"Moliner R, Girych M, Brunello CA, et al.: Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci 2023; 26: 1032–41.","DOI":"10.1038\/s41593-023-01316-5"},{"key":"10.3238\/arztebl.m2024.0224_ref26","doi-asserted-by":"crossref","unstructured":"Sekssaoui M, Bockaert J, Marin P, B\u00e9camel C: Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT(2A) receptor the unique player? Neuropsychopharmacology 2024; 49: 747–56.","DOI":"10.1038\/s41386-024-01794-6"},{"key":"10.3238\/arztebl.m2024.0224_ref27","doi-asserted-by":"crossref","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, et al.: Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–11.","DOI":"10.1056\/NEJMoa2032994"},{"key":"10.3238\/arztebl.m2024.0224_ref28","doi-asserted-by":"crossref","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al.: Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord 2023; 327: 120–7.","DOI":"10.1016\/j.jad.2023.01.108"},{"key":"10.3238\/arztebl.m2024.0224_ref29","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnder G, Brand M, K\u00e4rtner L, et al.: [Are psychedelics fast acting antidepressant agents?]. Nervenarzt 2022; 93: 254–62.","DOI":"10.1007\/s00115-021-01255-1"},{"key":"10.3238\/arztebl.m2024.0224_ref30","doi-asserted-by":"crossref","unstructured":"Hurst KT, Vogeley A, Greenstein DK, et al.: Long-term follow-up of participants in ketamine clinical trials for mood disorders. J Affect Disord 2024; 357: 134–7.","DOI":"10.1016\/j.jad.2024.04.062"},{"key":"10.3238\/arztebl.m2024.0224_ref31","doi-asserted-by":"crossref","unstructured":"Reif A, Bitter I, Buyze J, et al.: Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med 2023; 389: 1298–309.","DOI":"10.1056\/NEJMoa2304145"},{"key":"10.3238\/arztebl.m2024.0224_ref32","doi-asserted-by":"crossref","unstructured":"Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A: Methodological challenges in psychedelic drug trials: efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)—rationale and study design. Neuroscience Applied 2022; 1: 100104.","DOI":"10.1016\/j.nsa.2022.100104"},{"key":"10.3238\/arztebl.m2024.0224_ref33","unstructured":"Wirtz MA: Dorsch. Lexikon der Psychologie. Psychotherapie. https:\/\/dorsch.hogrefe.com\/stichwort\/psychotherapie (last accessed on 28 October 2024)."},{"key":"10.3238\/arztebl.m2024.0224_ref34","doi-asserted-by":"crossref","unstructured":"Cuijpers P, Miguel C, Harrer M, et al.: Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry 2023; 22: 105–15.","DOI":"10.1002\/wps.21069"},{"key":"10.3238\/arztebl.m2024.0224_ref35","doi-asserted-by":"crossref","unstructured":"Branchi I: The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinology 2011; 36: 339–51.","DOI":"10.1016\/j.psyneuen.2010.08.011"},{"key":"10.3238\/arztebl.m2024.0224_ref36","doi-asserted-by":"crossref","unstructured":"Doss MK, Považan M, Rosenberg MD et al.: Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry 2021; 11: 574.","DOI":"10.1038\/s41398-021-01706-y"},{"key":"10.3238\/arztebl.m2024.0224_ref37","doi-asserted-by":"crossref","unstructured":"Gukasyan N, Nayak SM: Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy. Transcult Psychiatry 2022; 59: 652–64.","DOI":"10.1177\/1363461520983684"},{"key":"10.3238\/arztebl.m2024.0224_ref38","doi-asserted-by":"crossref","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ: Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol 2022; 36: 258–72.","DOI":"10.1177\/02698811211069100"},{"key":"10.3238\/arztebl.m2024.0224_ref39","doi-asserted-by":"crossref","unstructured":"Simonsson O, Mosing MA, Osika W, et al.: Adolescent psychedelic use and psychotic or manic symptoms. JAMA Psychiatry 2024; 81: 579–85.","DOI":"10.1001\/jamapsychiatry.2024.0047"},{"key":"10.3238\/arztebl.m2024.0224_ref40","doi-asserted-by":"crossref","unstructured":"Evans J, Robinson OC, Argyri EK, et al.: Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS One 2023; 18: e0293349.","DOI":"10.1371\/journal.pone.0293349"},{"key":"10.3238\/arztebl.m2024.0224_ref41","doi-asserted-by":"crossref","unstructured":"Rosenblat JD, Meshkat S, Doyle Z, et al.: Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. Med 2024; 5: 190–200.e5.","DOI":"10.1016\/j.medj.2024.01.005"},{"key":"10.3238\/arztebl.m2024.0224_ref42","doi-asserted-by":"crossref","unstructured":"Raison CL, Sanacora G, Woolley J, et al.: Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. Jama 2023; 330: 843–53.","DOI":"10.1001\/jama.2023.14530"},{"key":"10.3238\/arztebl.m2024.0224_ref43","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al.: Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 2022; 387: 1637–48."},{"key":"10.3238\/arztebl.m2024.0224_ref44","doi-asserted-by":"crossref","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, et al.: Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 2023; 56: 101809.","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"10.3238\/arztebl.m2024.0224_ref45","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP, Ross S, Bhatt S, et al.: Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2022; 79: 953–62.","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"10.3238\/arztebl.m2024.0224_ref46","doi-asserted-by":"crossref","unstructured":"Davis AK, Barrett FS, May DG, et al.: Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2021; 78: 481–9.","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"10.3238\/arztebl.m2024.0224_ref47","doi-asserted-by":"crossref","unstructured":"Gukasyan N, Davis AK, Barrett FS, et al.: Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol 2022; 36: 151–8.","DOI":"10.1177\/02698811211073759"},{"key":"10.3238\/arztebl.m2024.0224_ref48","doi-asserted-by":"crossref","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, et al.: Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–11.","DOI":"10.1056\/NEJMoa2032994"},{"key":"10.3238\/arztebl.m2024.0224_ref49","doi-asserted-by":"crossref","unstructured":"Erritzoe D, Barba T, Greenway KT, et al.: Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. eClinicalMedicine, Volume 76, 102799.","DOI":"10.1016\/j.eclinm.2024.102799"},{"key":"10.3238\/arztebl.m2024.0224_ref50","doi-asserted-by":"crossref","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al.: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 2016; 30: 1181–97.","DOI":"10.1177\/0269881116675513"},{"key":"10.3238\/arztebl.m2024.0224_ref51","doi-asserted-by":"crossref","unstructured":"Ross S, Bossis A, Guss J, et al.: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016; 30: 1165–80.","DOI":"10.1177\/0269881116675512"},{"key":"10.3238\/arztebl.m2024.0224_ref52","doi-asserted-by":"crossref","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, et al.: Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 2020; 34: 155–66.","DOI":"10.1177\/0269881119897615"},{"key":"10.3238\/arztebl.m2024.0224_ref53","doi-asserted-by":"crossref","unstructured":"Agrawal M, Richards W, Beaussant Y, et al.: Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer 2024; 130: 1137–46.","DOI":"10.1002\/cncr.35010"},{"key":"10.3238\/arztebl.m2024.0224_ref54","doi-asserted-by":"crossref","unstructured":"Peck SK, Shao S, Gruen T, et al.: Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med 2023; 29: 1947–53.","DOI":"10.1038\/s41591-023-02455-9"},{"key":"10.3238\/arztebl.m2024.0224_ref55","doi-asserted-by":"crossref","unstructured":"Aaronson ST, van der Vaart A, Miller T, et al.: Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial. JAMA Psychiatry 2024; 81: 555–62.","DOI":"10.1001\/jamapsychiatry.2023.4685"},{"key":"10.3238\/arztebl.m2024.0224_ref56","doi-asserted-by":"crossref","unstructured":"Lewis BR, Garland EL, Byrne K, et al.: HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with cancer. J Pain Symptom Manage 2023; 66: 258–69.","DOI":"10.1016\/j.jpainsymman.2023.06.006"},{"key":"10.3238\/arztebl.m2024.0224_ref57","doi-asserted-by":"crossref","unstructured":"Schneier FR, Feusner J, Wheaton MG, et al.: Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J Psychiatr Res 2023; 161: 364–70.","DOI":"10.1016\/j.jpsychires.2023.03.031"},{"key":"10.3238\/arztebl.m2024.0224_ref58","doi-asserted-by":"crossref","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR: Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 2014; 28: 983–92.","DOI":"10.1177\/0269881114548296"},{"key":"10.3238\/arztebl.m2024.0224_ref59","doi-asserted-by":"crossref","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR: Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 2017; 43: 55–60.","DOI":"10.3109\/00952990.2016.1170135"},{"key":"10.3238\/arztebl.m2024.0224_ref60","doi-asserted-by":"crossref","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL: Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1735–40.","DOI":"10.4088\/JCP.v67n1110"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:26:32Z","timestamp":1734337592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":60,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0224","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}